Sirtuin 2 Antibody [S2R233-1] | 36-077

Sirtuin 2 Antibody [S2R233-1] | 36-077 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human

Homology: N/A

Immunogen: Recombinant human sirtuin 2.

Research Area: Cancer, Innate Immunity, Obesity

Tested Application: E, WB

Application: ELISA: (direct and indirect: 1:2, 000-1:5, 000) . Western Blot: (1:2, 000-1:5, 000 using ECL. Suggested blocking and dilution buffer is PBST containing 0.05% Tween 20 and 5% skim milk. Suggested incubation time is 1 hour at room temperature) . Optimal conditions must be determined individually for each application.

Specificiy: Recognizes human sirtuin 2. Detects a band of ~45kDa by Western blot.

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: N/A

Clonality: Monoclonal

Clone: S2R233-1

Isotype: IgG2b, kappa

Conjugate: Unconjugated

Physical State: Liquid

Buffer: Liquid. 0.2um-filtered solution in PBS, pH 7.4. Contains no preservatives.

Concentration: 1 mg/ml

Storage Condition: Stable for at least 1 year after receipt when stored at -20˚C.

Alternate Name: SIRT2; NAD-dependent Deacetylase Sirtuin-2; SIR2-like protein 2; SIR2L2

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: Sirtuin-2 is a NAD-dependent protein deacetylase, which deacetylates the 'Lys-40' of a-tubulin. It is involved in the control of mitotic exit in the cell cycle. Furthermore, a variety of age-associated diseases such as type 2 diabetes, obesity, osteoporosis, and Alzheimer’s disease are associated with sirtuins. Selective inhibition of Sirtuin-2 achieves neuroprotection and identifies Sirtuin-2 to be a potential therapeutic avenue in Huntington’s and Parkinson’s disease.